Joris Silon, U.S. Country President for AstraZeneca, talks about the need for a local supply chain in today's world during last week's Delaware's DNA Life Science Conference.
AstraZeneca has announced it will invest millions in one of its state-of-the-art facilities that focuses on packing protein therapeutics in a growing area in its portfolio.
AstraZeneca has recently completed a $2.4 billion deal for a California-based pharmaceutical company that gives the company a boost in next-generation cancer treatments.
